Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.10.18 | Visa Readies B2B Connect for Market | 382 | Business Wire | Visa's Distributed Ledger Platform Provides Groundbreaking "Digital Identity" for Clients; IBM and Bottomline Technologies Announced as New Partners for Commercial Launch Visa... ► Artikel lesen | |
21.10.18 | SOLO-1 Phase 3 Trial Demonstrates LYNPARZA (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | 97 | Business Wire | 60 Percent of Patients Receiving LYNPARZA Remained Progression-Free at Three Years Compared to 27 Percent on Placebo Following Platinum-Based Chemotherapy LYNPARZA Is the Only PARP... ► Artikel lesen | |
21.10.18 | Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma | 176 | Business Wire | Updated results presented at ESMO support planned submission of NDA in U.S. in 2019 Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202... ► Artikel lesen | |
21.10.18 | Servier and Taiho Oncology Announce Phase III LONSURF Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer | 90 | Business Wire | Positive Results from TAGS presented at ESMO 2018 Congress and Published in The Lancet Oncology Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co.,... ► Artikel lesen | |
21.10.18 | Genentech's Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors | 120 | Business Wire | - Entrectinib showed response irrespective of tumor type or spread to the central nervous system (CNS) - - Data will be submitted to global regulatory authorities, including the U.S.... ► Artikel lesen | |
21.10.18 | Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting | 126 | Business Wire | -- FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life - Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
GAMESTOP | 482 |
EVOTEC | 434 |
TUI | 332 |
NVIDIA | 276 |
BAYER | 249 |
DEUTSCHE BANK | 243 |
PLUG POWER | 233 |
NEL | 225 |
RHEINMETALL | 201 |
SIEMENS ENERGY | 185 |
COMMERZBANK | 175 |
TESLA | 159 |
BARRICK GOLD | 154 |
VOLKSWAGEN | 150 |
BASF | 147 |
BYD | 147 |
RWE | 147 |
DEUTSCHE LUFTHANSA | 137 |
ALLIANZ | 132 |
DEUTSCHE TELEKOM | 131 |
MERCEDES-BENZ | 124 |
ALIBABA | 118 |
RENK GROUP | 117 |
E.ON | 114 |
REDCARE PHARMACY | 112 |